✦ LIBER ✦

PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) + LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM

✍ Scribed by GH Mickisch; B Escudier; M Gore; S Walzer; MJ Nuijten

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN17 COST OF MANAGING SIDE EFFECTS OF F

✍ GH Mickisch; B Escudier; M Gore; G Procopio; S Walzer; MJ Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN42 COSTS OF MANAGING ADVERSE EVENTS O

✍ F Carlos; J Ramirez; A Aguirre 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

94 A REAL-LIFE COMPARATIVE EFFECTIVENESS

✍ G.H. Mickisch; B. Schwander; B. Escudier; J. Bellmunt; J.P. Maroto; C. Porta; S. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 87 KB